Skip to main content
Premium Trial:

Request an Annual Quote

Regulus, Biogen Ink New Agreement for Potential MS miRNA Biomarkers

NEW YORK (GenomeWeb) – Regulus Therapeutics today announced a new collaborative agreement with Biogen Idec to identify microRNAs for multiple sclerosis.

The agreement, to be carried out by the Regulus microMarkers division, will profile whole blood samples from a cohort of MS patients who have received Biogen's MS therapy in order to discover potential miRNA biomarkers. The deal replaces a prior agreement reached by the firms in 2012, under which Regulus used its technology to extract, profile, and analyze miRNAs from small volumes of blood. As part of that research, Regulus profiled more than 400 serum samples from MS patients and compared them with profiles from healthy volunteers.

Regulus will receive a $2 million upfront payment under the terms of the new deal and is eligible for additional payments upon certain milestones being achieved related to the identification of potential miRNA biomarkers.

"Our collaboration has made significant progress to date and we are hopeful to continue to help advance Biogen Idec's leading multiple sclerosis franchise in a meaningful way with our innovative technology platform." David Szekeres, chief business officer and general counsel for Regulus, said in a statement.

The Scan

Team Tracks Down Potential Blood Plasma Markers Linked to Heart Failure in Atrial Fibrillation Patients

Researchers in BMC Genomics found 10 differentially expressed proteins or metabolites that marked atrial fibrillation with heart failure cases.

Study Points to Synonymous Mutation Effects on E. Coli Enzyme Activity

Researchers in Nature Chemistry saw signs of enzyme activity shifts in the presence of synonymous mutations in a multiscale modeling analysis of three Escherichia coli genes.

Team Outlines Paternal Sample-Free Single-Gene Approach for Non-Invasive Prenatal Screening

With data for nearly 9,200 pregnant individuals, researchers in Genetics in Medicine demonstrate the feasibility of their carrier screening and reflex single-gene non-invasive prenatal screening approach.

Germline-Targeting HIV Vaccine Shows Promise in Phase I Trial

A National Institutes of Health-led team reports in Science that a broadly neutralizing antibody HIV vaccine induced bnAb precursors in 97 percent of those given the vaccine.